Johnson & Johnson's DePuy arm is recalling multiple lots of an orthopedic implant part prone to fracturing in some cases, and the FDA slapped its most-serious Class I status onto the effort. Limb loss is listed as one of the risks.
With more than 10,000 lawsuits already in the mix, Johnson & Johnson must deal with yet another patient's allegation's that company knowingly sold faulty metal hip implants and didn't warn the public.
Stryker's bottom line is already taking a hit from the escalating cost of its all-metal hip recalls. But lawsuits against the device maker are also rising, threatening to grab an even bigger chunk of the company's cash.
Johnson & Johnson has had enough with metal-on-metal and ceramic-on-metal hips, disclosing that it will leave those business lines entirely behind by the end of 2014.
After losing two jury trials, Johnson & Johnson/DePuy can now celebrate the fact that a jury has ruled in its favor regarding the company's ASR all metal hip implant.
Biomet posted a 9% sales hike last quarter thanks largely to its $280 million acquisition of DePuy's trauma business, but a ramp-up in costs and a hefty impairment charge rocketed its net loss up about 184%.
Johnson & Johnson's $8.3 million defeat in a U.S. jury trial over its ASR metal-on-metal hip implant could force it to settle a massive class action lawsuit in Australia over the same product.
A Johnson & Johnson executive testified that the company recalled its all-metal hip replacements because they didn't meet "clinical expectations," not because they were defective, but that doesn't quite jibe with internal documents.
Johnson & Johnson's DePuy unit is recalling the diaphyseal sleeve shipped with its Limb Preservation System, warning that the sleeve may fracture as patients walk, possibly resulting in infection or loss of limb.
Last week, Johnson & Johnson got hit with another suit over its now-recalled ASR hip implant. Now, the company and its DePuy subsidiary face litigation over their other hip device, the Pinnacle.